{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:52:18Z","timestamp":1793371938865,"version":"4.5.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-025-04884-4","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:10:12Z","timestamp":1769231412000},"page":"9323-9358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology"],"prefix":"10.1007","volume":"399","author":[{"given":"Rahaman","family":"Shaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Varikuppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvika","family":"Badampudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asra","family":"Jabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Anas","family":"Hamzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Uz","family":"Zehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeb","family":"Unnisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer Sadik","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaik","family":"Azeeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"15","key":"4884_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033705","volume":"13","author":"M Abdeladhim","year":"2022","unstructured":"Abdeladhim M, Karnell JL, Rieder SA (2022) In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Front Immunol 13(15):1033705","journal-title":"Front Immunol"},{"issue":"163","key":"4884_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103374","volume":"1","author":"A Addeo","year":"2021","unstructured":"Addeo A, Friedlaender A, Banna GL, Weiss GJ (2021) TMB or not TMB as a biomarker: that is the question. Crit Rev Oncol Hematol 1(163):103374","journal-title":"Crit Rev Oncol Hematol"},{"key":"4884_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume-title":"Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy","author":"L Ai","year":"2020","unstructured":"Ai L, Xu A, Xu J (2020) Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy, vol 18. pp 33\u201359"},{"issue":"1","key":"4884_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):92","journal-title":"J Hematol Oncol"},{"key":"4884_CR5","unstructured":"Alahmari M (n.d.) Discovery of anti-LAG-3 peptides and construction of a hybrid single-domain antibody phage display library for cancer immunotherapy. Doctoral dissertation, University of Missouri-Kansas City"},{"issue":"3","key":"4884_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032743","volume":"24","author":"JS Almeida","year":"2023","unstructured":"Almeida JS, Casanova JM, Santos-Rosa M, Tarazona R, Solana R, Rodrigues-Santos P (2023) Natural killer T-like cells: immunobiology and role in disease. Int J Mol Sci 24(3):2743","journal-title":"Int J Mol Sci"},{"key":"4884_CR7","unstructured":"Alquier L (n.d.) Regulatory harmonization in a resource-limited setting: the World Health Organization collaborative procedure for accelerated registration. Doctoral dissertation, University of Southern California"},{"issue":"8","key":"4884_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","volume":"23","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 23(8):561","journal-title":"Front Pharmacol"},{"issue":"5","key":"4884_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/ph14050447","volume":"14","author":"S Anand","year":"2021","unstructured":"Anand S, Chan TA, Hasan T, Maytin EV (2021) Current prospects for treatment of solid tumors via photodynamic, photothermal, or ionizing radiation therapies combined with immune checkpoint inhibition (a review). Pharmaceuticals 14(5):447","journal-title":"Pharmaceuticals"},{"issue":"11","key":"4884_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DA (2019) Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol 20(11):1425\u20131434","journal-title":"Nat Immunol"},{"issue":"25","key":"4884_CR11","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780\u20132788","journal-title":"J Clin Oncol"},{"issue":"13","key":"4884_CR12","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.3390\/ijms26136337","volume":"26","author":"PC Arriola Ben\u00edtez","year":"2025","unstructured":"Arriola Ben\u00edtez PC, Fusco M, Amorin R, Pic\u00f3n CR, Piccioni F, Victoria L, Rizzo MM, Malvicini M (2025) Unraveling the role of tumor-infiltrating immune cells in head and neck squamous cell carcinoma: implications for antitumor immune responses and immunotherapy. Int J Mol Sci 26(13):6337","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4884_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094\u20131100","journal-title":"Nat Med"},{"issue":"3","key":"4884_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00262-008-0576-4","volume":"58","author":"CN Baxevanis","year":"2009","unstructured":"Baxevanis CN, Perez SA, Papamichail M (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58(3):317\u2013324","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"4884_CR15","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1200\/JCO.2004.05.063","volume":"22","author":"AB Benson III","year":"2004","unstructured":"Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408\u20133419","journal-title":"J Clin Oncol"},{"issue":"10","key":"4884_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O (2023) Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res 29(10):1835\u20131854","journal-title":"Clin Cancer Res"},{"key":"4884_CR17","doi-asserted-by":"publisher","first-page":"100767","DOI":"10.1016\/j.oor.2025.100767","volume":"11","author":"R Bhushan","year":"2025","unstructured":"Bhushan R, Rai S, Jangra P, Sonker P, Singh N, Lakshami R, Philip RR, Gakhar S, Dakal TC (2025) The role of artificial intelligence in predicting cancer immunotherapy response. Oral Oncology Reports 11:100767","journal-title":"Oral Oncology Reports"},{"issue":"13","key":"4884_CR18","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"20","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ (2022) Managing the TME to improve the efficacy of cancer therapy. Front Immunol 20(13):954992","journal-title":"Front Immunol"},{"issue":"10","key":"4884_CR19","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.7150\/ijbs.93697","volume":"20","author":"R Birnboim-Perach","year":"2024","unstructured":"Birnboim-Perach R, Benhar I (2024) Using combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment. Int J Biol Sci 20(10):3911","journal-title":"Int J Biol Sci"},{"issue":"2","key":"4884_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1484","volume":"13","author":"B Bischl","year":"2023","unstructured":"Bischl B, Binder M, Lang M, Pielok T, Richter J, Coors S, Thomas J, Ullmann T, Becker M, Boulesteix AL, Deng D (2023) Hyperparameter optimization: foundations, algorithms, best practices, and open challenges. Wires Data Min Knowl Discov 13(2):e1484","journal-title":"Wires Data Min Knowl Discov"},{"issue":"15","key":"4884_CR21","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.3390\/cancers15153972","volume":"15","author":"E Boopathi","year":"2023","unstructured":"Boopathi E, Den RB, Thangavel C (2023) Innate immune system in the context of radiation therapy for cancer. Cancers 15(15):3972","journal-title":"Cancers"},{"issue":"3","key":"4884_CR22","doi-asserted-by":"publisher","first-page":"e007841","DOI":"10.1136\/jitc-2023-007841","volume":"12","author":"D Bottomly","year":"2024","unstructured":"Bottomly D, McWeeney S (2024) Just how transformative will AI\/ML be for immuno-oncology? J Immunother Cancer 12(3):e007841","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4884_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab025","volume":"2","author":"SE Burnell","year":"2022","unstructured":"Burnell SE, Capitani L, MacLachlan BJ, Mason GH, Gallimore AM, Godkin A (2022) Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunother Adv 2(1):ltab025","journal-title":"Immunother Adv"},{"issue":"6","key":"4884_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG (2024) Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol 24(6):399\u2013416","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4884_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y (2023) Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol 16(1):101","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4884_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19(1):565\u2013594","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"4884_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines4030028","volume":"4","author":"B Chaudhary","year":"2016","unstructured":"Chaudhary B, Elkord E (2016) Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines 4(3):28","journal-title":"Vaccines"},{"issue":"8","key":"4884_CR28","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1111\/cas.16205","volume":"115","author":"A Chavanton","year":"2024","unstructured":"Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, Garrido C (2024) LAG-3: recent developments in combinational therapies in cancer. Cancer Sci 115(8):2494\u20132505","journal-title":"Cancer Sci"},{"issue":"1","key":"4884_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3747\/co.25.4096","volume":"26","author":"PK Cheema","year":"2019","unstructured":"Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V (2019) Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol 26(1):37","journal-title":"Curr Oncol"},{"key":"4884_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111647","author":"W Chen","year":"2022","unstructured":"Chen W, Teo JM, Yau SW, Wong MY, Lok CN, Che CM, Javed A, Huang Y, Ma S, Ling GS (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2022.111647","journal-title":"Cell Rep"},{"issue":"9","key":"4884_CR31","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384\u20133391","journal-title":"J Clin Invest"},{"issue":"10","key":"4884_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105282","volume":"22","author":"L Chocarro","year":"2021","unstructured":"Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fern\u00e1ndez-Rubio L, Morente P, Fern\u00e1ndez-Hinojal G, Echaide M, Garnica M, Ramos P (2021) Understanding LAG-3 signaling. Int J Mol Sci 22(10):5282","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4884_CR33","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD (2022) Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol 19(12):775\u2013790","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4884_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R (2023) Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer 22(1):93","journal-title":"Mol Cancer"},{"issue":"6","key":"4884_CR35","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/cancers13061188","volume":"13","author":"IT Chyuan","year":"2021","unstructured":"Chyuan IT, Chu CL, Hsu PN (2021) Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers 13(6):1188","journal-title":"Cancers"},{"issue":"9","key":"4884_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004884","volume":"10","author":"JW Conway","year":"2022","unstructured":"Conway JW, Rawson RV, Lo S, Ahmed T, Vergara IA, Gide TN, Attrill GH, Carlino MS, Saw RP, Thompson JF, Spillane AJ (2022) Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. J Immunother Cancer 10(9):e004884","journal-title":"J Immunother Cancer"},{"issue":"24","key":"4884_CR37","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","volume":"73","author":"BD Curti","year":"2013","unstructured":"Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Can Res 73(24):7189\u20137198","journal-title":"Can Res"},{"issue":"14","key":"4884_CR38","doi-asserted-by":"publisher","first-page":"1252274","DOI":"10.3389\/fimmu.2023.1252274","volume":"27","author":"O Dadas","year":"2023","unstructured":"Dadas O, Allen JD, Buchan SL, Kim J, Chan HC, Mockridge CI, Duriez PJ, Rogel A, Crispin M, Al-Shamkhani A (2023) Fc\u03b3 receptor binding is required for maximal immunostimulation by CD70-Fc. Front Immunol 27(14):1252274","journal-title":"Front Immunol"},{"issue":"97","key":"4884_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.artmed.2019.01.006","volume":"1","author":"M Daoud","year":"2019","unstructured":"Daoud M, Mayo M (2019) A survey of neural network-based cancer prediction models from microarray data. Artif Intell Med 1(97):204\u2013214","journal-title":"Artif Intell Med"},{"issue":"4","key":"4884_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22(4):39","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"4884_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.897750","volume":"9","author":"G Delfanti","year":"2022","unstructured":"Delfanti G, Dellabona P, Casorati G, Fedeli M (2022) Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment. Front Med 9(9):897750","journal-title":"Front Med"},{"key":"4884_CR42","doi-asserted-by":"crossref","unstructured":"Desai NB, Hannan R, Timmerman RD (2024) Stereotactic ablative radiotherapy (SAbR) for primary prostate cancer. In: Stereotactic radiosurgery and stereotactic body radiation therapy: a comprehensive guide. Cham, Springer Nature Switzerland, pp 293\u2013307","DOI":"10.1007\/978-3-031-67743-4_24"},{"issue":"2","key":"4884_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","volume":"140","author":"SM Domchek","year":"2016","unstructured":"Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, Mitchell G, Fried G, Stemmer SM, Hubert A (2016) Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 140(2):199\u2013203","journal-title":"Gynecol Oncol"},{"issue":"11","key":"4884_CR44","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1586\/1744666X.2014.962515","volume":"10","author":"B Dong","year":"2014","unstructured":"Dong B, Minze LJ, Xue W, Chen W (2014) Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Expert Rev Clin Immunol 10(11):1547\u20131557","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"4884_CR45","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3390\/cancers13081949","volume":"13","author":"Y Dong","year":"2021","unstructured":"Dong Y, Wong JS, Sugimura R, Lam KO, Li B, Kwok GG, Leung R, Chiu JW, Cheung TT, Yau T (2021) Recent advances and future prospects in immune checkpoint (ICI)-based combination therapy for advanced HCC. Cancers 13(8):1949","journal-title":"Cancers"},{"issue":"1","key":"4884_CR46","doi-asserted-by":"publisher","first-page":"e001570","DOI":"10.1136\/bmjopen-2012-001570","volume":"3","author":"C Doyle","year":"2013","unstructured":"Doyle C, Lennox L, Bell D (2013) A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open 3(1):e001570","journal-title":"BMJ Open"},{"issue":"11","key":"4884_CR47","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1373\/clinchem.2008.110056","volume":"54","author":"MJ Duffy","year":"2008","unstructured":"Duffy MJ, Crown J (2008) A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54(11):1770\u20131779","journal-title":"Clin Chem"},{"issue":"2","key":"4884_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ctrv.2010.07.004","volume":"37","author":"MJ Duffy","year":"2011","unstructured":"Duffy MJ, O\u2019Donovan N, Crown J (2011) Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 37(2):151\u2013159","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"4884_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb\u00e9 C (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522\u2013530","journal-title":"Lancet Oncol"},{"issue":"2","key":"4884_CR50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/ijms26020515","volume":"26","author":"S Fanijavadi","year":"2025","unstructured":"Fanijavadi S, Thomassen M, Jensen LH (2025) Targeting triple NK cell suppression mechanisms: a comprehensive review of biomarkers in pancreatic cancer therapy. Int J Mol Sci 26(2):515","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4884_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BY, Zhang CC, Fu YX, Weissman IL (2019) Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19(10):568\u2013586","journal-title":"Nat Rev Cancer"},{"issue":"28","key":"4884_CR52","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","volume":"28","author":"RL Ferris","year":"2010","unstructured":"Ferris RL, Jaffee EM, Ferrone S (2010) Tumor antigen\u2013targeted, monoclonal antibody\u2013based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28(28):4390\u20134399","journal-title":"J Clin Oncol"},{"issue":"2","key":"4884_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/0008-5472.CAN-08-3529","volume":"69","author":"L Fong","year":"2009","unstructured":"Fong L, Kwek SS, O\u2019Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Can Res 69(2):609\u2013615","journal-title":"Can Res"},{"issue":"23","key":"4884_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312848","volume":"25","author":"O Franzese","year":"2024","unstructured":"Franzese O (2024) Tumor microenvironment drives the cross-talk between co-stimulatory and inhibitory molecules in tumor-infiltrating lymphocytes: implications for optimizing immunotherapy outcomes. Int J Mol Sci 25(23):12848","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4884_CR55","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/2326-6066.CIR-20-0834","volume":"9","author":"DJ Friedman","year":"2021","unstructured":"Friedman DJ, Crotts SB, Shapiro MJ, Rajcula M, McCue S, Liu X, Khazaie K, Dong H, Shapiro VS (2021) ST8sia6 promotes tumor growth in mice by inhibiting immune responses. Cancer Immunol Res 9(8):952\u2013966","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4884_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/imr.12574","volume":"280","author":"AD Garg","year":"2017","unstructured":"Garg AD, Agostinis P (2017) Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev 280(1):126\u2013148","journal-title":"Immunol Rev"},{"issue":"4","key":"4884_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/pharmaceutics13040547","volume":"13","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L (2021) Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics 13(4):547","journal-title":"Pharmaceutics"},{"issue":"7","key":"4884_CR58","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1002\/onco.13812","volume":"26","author":"S George","year":"2021","unstructured":"George S, Bell EJ, Zheng Y, Kim R, White J, Devgan G, Smith J, Lal LS, Engel-Nitz NM, Liu FX (2021) The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors. Oncologist 26(7):e1205\u2013e1215","journal-title":"Oncologist"},{"issue":"38","key":"4884_CR59","doi-asserted-by":"publisher","first-page":"35223","DOI":"10.1074\/jbc.R100025200","volume":"276","author":"RN Germain","year":"2001","unstructured":"Germain RN (2001) The T cell receptor for antigen: signaling and ligand discrimination. J Biol Chem 276(38):35223\u201335226","journal-title":"J Biol Chem"},{"issue":"8","key":"4884_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/intimm\/dxq049","volume":"22","author":"M Ghiotto","year":"2010","unstructured":"Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nun\u00e8s JA, Olive D (2010) PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 22(8):651\u2013660","journal-title":"Int Immunol"},{"issue":"5","key":"4884_CR61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/fampra\/cmr013","volume":"28","author":"LG Glynn","year":"2011","unstructured":"Glynn LG, Valderas JM, Healy P, Burke E, Newell J, Gillespie P, Murphy AW (2011) The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract 28(5):516\u2013523","journal-title":"Fam Pract"},{"issue":"4","key":"4884_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R (2017) PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 14(4):203\u2013220","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4884_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0634-9","volume":"7","author":"M Grapin","year":"2019","unstructured":"Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G (2019) Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer 7(1):160","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4884_CR64","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1200\/JCO.2004.08.173","volume":"22","author":"LL Gunderson","year":"2004","unstructured":"Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O\u2019Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22(10):1785\u20131796","journal-title":"J Clin Oncol"},{"issue":"11","key":"4884_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632540","volume":"15","author":"M Guo","year":"2021","unstructured":"Guo M, Sun C, Qian Y, Zhu L, Ta N, Wang G, Zheng J, Guo F, Liu Y (2021) Proliferation of highly cytotoxic human natural killer cells by OX40L armed NK-92 with secretory neoleukin-2\/15 for cancer immunotherapy. Front Oncol 15(11):632540","journal-title":"Front Oncol"},{"issue":"12","key":"4884_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258538","volume":"14","author":"J Guo","year":"2023","unstructured":"Guo J, Wang S, Gao Q (2023) An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer. Front Immunol 14(12):1258538","journal-title":"Front Immunol"},{"issue":"10","key":"4884_CR67","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2217\/fon-2017-0531","volume":"14","author":"CE Handy","year":"2017","unstructured":"Handy CE, Antonarakis ES (2017) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14(10):907\u2013917","journal-title":"Future Oncol"},{"issue":"2","key":"4884_CR68","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-7553","volume":"9","author":"J He","year":"2021","unstructured":"He J, Ouyang W, Zhao W, Shao L, Li B, Liu B, Wang D, Han-Zhang H, Zhang Z, Shao L, Li W (2021) Distinctive genomic characteristics in POLE\/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Ann Transl Med 9(2):129","journal-title":"Ann Transl Med"},{"issue":"1","key":"4884_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00262-017-2059-y","volume":"67","author":"JP Hebb","year":"2018","unstructured":"Hebb JP, Mosley AR, Vences-Catal\u00e1n F, Rajasekaran N, Ros\u00e9n A, Ellmark P, Felsher DW (2018) Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother 67(1):47\u201360","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"4884_CR70","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.clinthera.2017.03.018","volume":"39","author":"IB Hirsch","year":"2017","unstructured":"Hirsch IB, Martinez J, Dorsey ER, Finken G, Fleming A, Gropp C, Home P, Kaufer DI, Papapetropoulos S (2017) Incorporating site-less clinical trials into drug development: a framework for action. Clin Ther 39(5):1064\u20131076","journal-title":"Clin Ther"},{"issue":"1","key":"4884_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y (2024) Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther 9(1):68","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"4884_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378739","volume":"11","author":"J Huang","year":"2024","unstructured":"Huang J, Yang Q, Wang W, Huang J (2024) CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy. Front Immunol 11(15):1378739","journal-title":"Front Immunol"},{"issue":"6","key":"4884_CR73","first-page":"1973","volume":"27","author":"D Hui","year":"2019","unstructured":"Hui D, Paiva CE, Del Fabbro EG, Steer C, Naberhuis J, van de Wetering M, Fern\u00e1ndez-Ortega P, Morita T, Suh SY, Bruera E, Mori M (2019) Prognostication in advanced cancer: update and directions for future research. Support Care Cancer 27(6):1973\u20131984","journal-title":"Support Care Cancer"},{"issue":"1","key":"4884_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/gastro\/goz061","volume":"8","author":"N Huyghe","year":"2020","unstructured":"Huyghe N, Baldin P, Van den Eynde M (2020) Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumors? Gastroenterol Rep 8(1):11\u201324","journal-title":"Gastroenterol Rep"},{"issue":"3","key":"4884_CR75","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1080\/09546634.2021.1882659","volume":"33","author":"J Hwang","year":"2022","unstructured":"Hwang J, Lio PA (2022) Topical corticosteroid withdrawal (\u2018steroid addiction\u2019): an update of a systematic review. J Dermatol Treat 33(3):1293\u20131298","journal-title":"J Dermatol Treat"},{"issue":"26","key":"4884_CR76","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107424118","volume":"118","author":"I Ibarlucea-Benitez","year":"2021","unstructured":"Ibarlucea-Benitez I, Weitzenfeld P, Smith P, Ravetch JV (2021) Siglecs-7\/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc Natl Acad Sci U S A 118(26):e2107424118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4884_CR77","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4254\/wjh.v14.i1.168","volume":"14","author":"SM Jeyakumar","year":"2022","unstructured":"Jeyakumar SM, Vajreswari A (2022) Stearoyl-CoA desaturase 1: a potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence. World J Hepatol 14(1):168","journal-title":"World J Hepatol"},{"issue":"2","key":"4884_CR78","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd2683","volume":"8","author":"J Jia","year":"2009","unstructured":"Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8(2):111\u2013128","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4884_CR79","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00262-022-03247-9","volume":"72","author":"G Jiang","year":"2023","unstructured":"Jiang G, Ng YY, Tay JC, Du Z, Xiao L, Wang S, Zhu J (2023) Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis. Cancer Immunol Immunother 72(1):223\u2013234","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4884_CR80","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R (2023) Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 22(3):213\u2013234","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"4884_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557006","volume":"12","author":"Y Jin","year":"2025","unstructured":"Jin Y, Jia Z, Xia X, Gordon NB, Ludwig JA, Somaiah N, Li S (2025) Anti-CD137 agonist antibody\u2013independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. Front Immunol 12(16):1557006","journal-title":"Front Immunol"},{"issue":"7","key":"4884_CR82","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/1078-0432.CCR-16-2318","volume":"23","author":"BA Johnson III","year":"2017","unstructured":"Johnson BA III, Yarchoan M, Lee V, Laheru DA, Jaffee EM (2017) Strategies for increasing pancreatic tumor immunogenicity. Clin Cancer Res 23(7):1656\u20131669","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4884_CR83","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19(4):254\u2013267","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"4884_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, Mackiewicz A (2023) Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review. Cells 12(17):2159","journal-title":"Cells"},{"issue":"3","key":"4884_CR85","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrd3651","volume":"11","author":"GJ Kelloff","year":"2012","unstructured":"Kelloff GJ, Sigman CC (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11(3):201\u2013214","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4884_CR86","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.21037\/tlcr-20-253","volume":"10","author":"L Kepka","year":"2021","unstructured":"Kepka L, Socha J (2021) Dose and fractionation schedules in radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res 10(4):1969","journal-title":"Transl Lung Cancer Res"},{"issue":"17","key":"4884_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/1533033818798792","volume":"12","author":"M Khan","year":"2018","unstructured":"Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu M, Yuan Y (2018) SRS in combination with ipilimumab: a promising new dimension for treating melanoma brain metastases. Technol Cancer Res Treat 12(17):1533033818798792","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"4884_CR88","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/livers2030011","volume":"2","author":"A Khan","year":"2022","unstructured":"Khan A, Chauhan K, Ross H, Parra NS, Magagna J, Wang M, Zhu P, Erwin R, Halegoua-DeMarzio D (2022) A comprehensive review on the use of herbal dietary supplements in the USA, reasons for their use, and review of potential hepatotoxicity. Livers 2(3):119\u2013138","journal-title":"Livers"},{"issue":"10","key":"4884_CR89","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00262-024-03777-4","volume":"73","author":"NH Kim","year":"2024","unstructured":"Kim NH, Lee J, Kim SH, Kang SH, Bae S, Yu CH, Seo J, Kim HT (2024) ALK5\/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. Cancer Immunol Immunother 73(10):190","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"4884_CR90","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/01.mlr.0000223480.52713.b9","volume":"44","author":"CN Klabunde","year":"2006","unstructured":"Klabunde CN, Harlan LC, Warren JL (2006) Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 44(10):921\u2013928","journal-title":"Med Care"},{"issue":"3","key":"4884_CR91","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/aje\/kwh029","volume":"159","author":"K Kleinman","year":"2004","unstructured":"Kleinman K, Lazarus R, Platt R (2004) A generalized linear mixed models approach for detecting incident clusters of disease in small areas, with an application to biological terrorism. Am J Epidemiol 159(3):217\u2013224","journal-title":"Am J Epidemiol"},{"issue":"4","key":"4884_CR92","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","volume":"16","author":"LM Krug","year":"2015","unstructured":"Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, \u00d6hman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM (2015) Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16(4):447\u2013456","journal-title":"Lancet Oncol"},{"key":"4884_CR93","doi-asserted-by":"crossref","unstructured":"Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325(17):1205\u20131209","DOI":"10.1056\/NEJM199110243251703"},{"issue":"5256","key":"4884_CR94","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734\u20131736","journal-title":"Science"},{"issue":"3","key":"4884_CR95","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78(3):447\u2013464","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4884_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39119-8","volume":"14","author":"MP Lenza","year":"2023","unstructured":"Lenza MP, Egia-Mendikute L, Anto\u00f1ana-Vildosola A, Soares CO, Coelho H, Corzana F, Bosch A, Manisha P, Quintana JI, Oyenarte I, Unione L (2023) Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b. Nat Commun 14(1):3496","journal-title":"Nat Commun"},{"issue":"1","key":"4884_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li D, Wu M (2021) Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 6(1):291","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4884_CR98","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1016\/j.cllc.2021.05.004","volume":"22","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang Y, Jia X, Jiang P, Mao Z, Liang T, Du Y, Zhang J, Zhang G, Niu G, Guo H (2021) Effect of immune-related adverse events and pneumonitis on prognosis in advanced non\u2013small cell lung cancer: a comprehensive systematic review and meta-analysis. Clin Lung Cancer 22(6):e889-900","journal-title":"Clin Lung Cancer"},{"issue":"15","key":"4884_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1365966","volume":"17","author":"J Li","year":"2025","unstructured":"Li J, Zheng L, Liu C, Liu W, Li Y, Wang D, Jiang T (2025) Incidences of pneumonitis associated with the combination of radiotherapy and immune checkpoint inhibitors in lung cancer: a systematic review and meta-analysis. Front Oncol 17(15):1365966","journal-title":"Front Oncol"},{"issue":"18","key":"4884_CR100","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","volume":"76","author":"E Limagne","year":"2016","unstructured":"Limagne E, Euvrard R, Thibaudin M, R\u00e9b\u00e9 C, Derang\u00e8re V, Chevriaux A, Boidot R, V\u00e9gran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L (2016) Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX\u2013bevacizumab drug treatment regimen. Cancer Res 76(18):5241\u20135252","journal-title":"Cancer Res"},{"issue":"1","key":"4884_CR101","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2452277","volume":"17","author":"A Lin","year":"2025","unstructured":"Lin A, Jiang A, Huang L, Li Y, Zhang C, Zhu L, Mou W, Liu Z, Zhang J, Cheng Q, Wei T (2025) From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy. Gut Microbes 17(1):2452277","journal-title":"Gut Microbes"},{"issue":"16","key":"4884_CR102","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1021\/bi00131a002","volume":"31","author":"JM Liu","year":"1992","unstructured":"Liu JM, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, Cohen P, MacKintosh C, Klee CB, Schreiber SL (1992) Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31(16):3896\u20133901","journal-title":"Biochemistry"},{"issue":"1","key":"4884_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8(1):198","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4884_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KT, Guan XY (2024) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther 9(1):175","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"4884_CR105","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463\u2013482","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"4884_CR106","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","volume":"25","author":"C Luri-Rey","year":"2025","unstructured":"Luri-Rey C, Teijeira \u00c1, Wculek SK, de Andrea C, Herrero C, Lopez-Janeiro A, Rodr\u00edguez-Ruiz ME, Heras I, Aggelakopoulou M, Berraondo P, Sancho D (2025) Cross-priming in cancer immunology and immunotherapy. Nat Rev Cancer 25(4):249\u2013273","journal-title":"Nat Rev Cancer"},{"key":"4884_CR107","doi-asserted-by":"crossref","unstructured":"Ma F, Li Y, Li Q, Qiu M, Gao J, Zhi S, Su L, Zhao B, Ji H, Han J (2015) Faitcrowd: fine grained truth discovery for crowdsourced data aggregation. In: Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. pp 745\u2013754","DOI":"10.1145\/2783258.2783314"},{"issue":"10","key":"4884_CR108","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00262-004-0577-x","volume":"53","author":"KJ Malmberg","year":"2004","unstructured":"Malmberg KJ (2004) Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53(10):879\u2013892","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"4884_CR109","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/brainsci14080764","volume":"14","author":"A Malvaso","year":"2024","unstructured":"Malvaso A, Giglio P, Diamanti L, Gastaldi M, Vegezzi E, Pace A, Bini P, Marchioni E (2024) Unravelling the acute, chronic and steroid-refractory management of high-grade neurological immune-related adverse events: a call to action. Brain Sci 14(8):764","journal-title":"Brain Sci"},{"issue":"2","key":"4884_CR110","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/eji.201545839","volume":"46","author":"SM Man","year":"2016","unstructured":"Man SM, Karki R, Kanneganti TD (2016) AIM2 inflammasome in infection, cancer, and autoimmunity: role in DNA sensing, inflammation, and innate immunity. Eur J Immunol 46(2):269\u2013280","journal-title":"Eur J Immunol"},{"issue":"1","key":"4884_CR111","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23(1):64","journal-title":"Cancer Cell Int"},{"issue":"12","key":"4884_CR112","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Foppen MG, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA (2016) Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22(12):2908\u20132918","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4884_CR113","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamaoncol.2019.3857","volume":"6","author":"JS Mayadev","year":"2020","unstructured":"Mayadev JS, Enserro D, Lin YG, Da Silva DM, Lankes HA, Aghajanian C, Ghamande S, Moore KN, Kennedy VA, Fracasso PM, Schilder RJ (2020) Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer. JAMA Oncol 6(1):92\u201399","journal-title":"JAMA Oncol"},{"issue":"9","key":"4884_CR114","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ctrv.2014.06.012","volume":"40","author":"D McDermott","year":"2014","unstructured":"McDermott D, Lebb\u00e9 C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40(9):1056\u20131064","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"4884_CR115","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004709","volume":"10","author":"MM Melssen","year":"2022","unstructured":"Melssen MM, Fisher CT, Slingluff CL, Melief CJ (2022) Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer. J Immunother Cancer 10(9):e004709","journal-title":"J Immunother Cancer"},{"issue":"98","key":"4884_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107889","volume":"1","author":"X Meng","year":"2021","unstructured":"Meng X, Sun X, Liu Z, He Y (2021) A novel era of cancer\/testis antigen in cancer immunotherapy. Int Immunopharmacol 1(98):107889","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4884_CR117","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV (2021) Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg 25(1):59\u201376","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"4884_CR118","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","volume":"26","author":"A Murao","year":"2021","unstructured":"Murao A, Aziz M, Wang H, Brenner M, Wang P (2021) Release mechanisms of major DAMPs. Apoptosis 26(3):152\u2013162","journal-title":"Apoptosis"},{"issue":"1","key":"4884_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20(1):44","journal-title":"Cell Commun Signal"},{"issue":"1","key":"4884_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122387","volume":"338","author":"S Najafi","year":"2024","unstructured":"Najafi S, Mortezaee K (2024) Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: a focus on anti PD-1\/PD-L1 antibodies. Life Sci 338(1):122387","journal-title":"Life Sci"},{"issue":"6","key":"4884_CR121","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-23-2568","volume":"30","author":"S Nakamichi","year":"2024","unstructured":"Nakamichi S, Kubota K, Misumi T, Kondo T, Murakami S, Shiraishi Y, Imai H, Harada D, Isobe K, Itani H, Takata S (2024) Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non\u2013small cell lung cancer: TORG1937 (DATE study). Clin Cancer Res 30(6):1104\u20131110","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4884_CR122","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jtho.2019.02.008","volume":"14","author":"MV Negrao","year":"2019","unstructured":"Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL (2019) PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non\u2013small cell lung cancer. J Thorac Oncol 14(6):1021\u20131031","journal-title":"J Thorac Oncol"},{"issue":"16","key":"4884_CR123","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","volume":"187","author":"SF Ngiow","year":"2024","unstructured":"Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, Chen Q, Khan O, Wu JE, Alcalde V, Flowers AJ (2024) LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell 187(16):4336\u20134354","journal-title":"Cell"},{"issue":"1","key":"4884_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0218-5","volume":"5","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD (2017) Combination immunotherapy: a road map. J Immunother Cancer 5(1):16","journal-title":"J Immunother Cancer"},{"key":"4884_CR125","doi-asserted-by":"crossref","unstructured":"Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M (2006) Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening\u2014a report from the American Society of Clinical Oncology. J Clin Oncol 25(1):146\u2013162","DOI":"10.1200\/JCO.2006.09.7030"},{"issue":"1","key":"4884_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02846-3","volume":"42","author":"B Palermo","year":"2023","unstructured":"Palermo B, Franzese O, Frisullo G, D\u2019Ambrosio L, Panetta M, Campo G, D\u2019Andrea D, Sperduti I, De Nicola F, Goeman F, Gallina F (2023) CD28\/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients\u2019 survival and ICB response. J Exp Clin Cancer Res 42(1):287","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"4884_CR127","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK (2017) Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171(7):1678\u20131691","journal-title":"Cell"},{"key":"4884_CR128","unstructured":"Papazoglou D (n.d.) Modelling the ability of targeted drugs and immunotherapy to modulate anti-tumor T cell activity in Chronic Lymphocytic Leukaemia. Doctoral dissertation, King's College London"},{"issue":"10","key":"4884_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.830208","volume":"8","author":"K Park","year":"2022","unstructured":"Park K, Veena MS, Shin DS (2022) Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies. Front Cell Dev Biol 8(10):830208","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"4884_CR130","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ (2018) Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48(3):417\u2013433","journal-title":"Immunity"},{"issue":"8","key":"4884_CR131","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40629-019-00111-8","volume":"28","author":"M Paulmann","year":"2019","unstructured":"Paulmann M, Mockenhaupt M (2019) Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo J Int 28(8):311\u2013326","journal-title":"Allergo J Int"},{"issue":"10","key":"4884_CR132","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazi\u00e8res J, Hermes B, Cicin I, Medgyasszay B, Rodr\u00edguez-Cid J, Okamoto I (2020) A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 15(10):1657\u20131669","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4884_CR133","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1600-065X.2008.00649.x","volume":"224","author":"KS Peggs","year":"2008","unstructured":"Peggs KS, Quezada SA, Allison JP (2008) Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224(1):141\u2013165","journal-title":"Immunol Rev"},{"issue":"11","key":"4884_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00784","volume":"7","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, de Reyni\u00e8s A, Saut\u00e8s-Fridman C, Fridman WH (2020) The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol 7(11):784","journal-title":"Front Immunol"},{"issue":"7","key":"4884_CR135","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.immuni.2023.06.007","volume":"56","author":"AC Pichler","year":"2023","unstructured":"Pichler AC, Carri\u00e9 N, Cuisinier M, Ghazali S, Voisin A, Axisa PP, Tosolini M, Mazzotti C, Golec DP, Maheo S, Do SL (2023) TCR-independent CD137 (4\u20131BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation. Immunity 56(7):1631\u20131648","journal-title":"Immunity"},{"issue":"3","key":"4884_CR136","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","volume":"12","author":"D Plana","year":"2022","unstructured":"Plana D, Palmer AC, Sorger PK (2022) Independent drug action in combination therapy: implications for precision oncology. Cancer Discov 12(3):606\u2013624","journal-title":"Cancer Discov"},{"issue":"8","key":"4884_CR137","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1172\/JCI120775","volume":"128","author":"A Popovic","year":"2018","unstructured":"Popovic A, Jaffee EM, Zaidi N (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128(8):3209\u20133218","journal-title":"J Clin Invest"},{"issue":"17","key":"4884_CR138","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982","journal-title":"J Clin Oncol"},{"issue":"3","key":"4884_CR139","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-021-00781-x","volume":"19","author":"H Prendeville","year":"2022","unstructured":"Prendeville H, Lynch L (2022) Diet, lipids, and antitumor immunity. Cell Mol Immunol 19(3):432\u2013444","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"4884_CR140","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/cancers13040678","volume":"13","author":"A Procureur","year":"2021","unstructured":"Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA (2021) Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: a comprehensive review and latest developments. Cancers 13(4):678","journal-title":"Cancers"},{"issue":"13","key":"4884_CR141","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.7150\/jca.77619","volume":"13","author":"Z Quan","year":"2022","unstructured":"Quan Z, Yang Y, Zheng H, Zhan Y, Luo J, Ning Y, Fan S (2022) Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer. J Cancer 13(13):3434","journal-title":"J Cancer"},{"issue":"2","key":"4884_CR142","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/med4.62","volume":"2","author":"GM Raj","year":"2024","unstructured":"Raj GM, Dananjayan S, Gudivada KK (2024) Applications of artificial intelligence and machine learning in clinical medicine: what lies ahead? Med Adv 2(2):202\u2013204","journal-title":"Med Adv"},{"key":"4884_CR143","doi-asserted-by":"publisher","DOI":"10.1177\/1756287218823485","volume":"11","author":"A Rao","year":"2019","unstructured":"Rao A, Patel MR (2019) A review of avelumab in locally advanced and metastatic bladder cancer. Ther Adv Urol 11:1756287218823485","journal-title":"Ther Adv Urol"},{"issue":"9","key":"4884_CR144","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14712598.2023.2249396","volume":"23","author":"WL Redmond","year":"2023","unstructured":"Redmond WL (2023) Challenges and opportunities in the development of combination immunotherapy with OX40 agonists. Expert Opin Biol Ther 23(9):901\u2013912","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"4884_CR145","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00920-z","volume":"22","author":"JE Reuss","year":"2020","unstructured":"Reuss JE, Suresh K, Naidoo J (2020) Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond. Curr Oncol Rep 22(6):56","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4884_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21550-4","volume":"12","author":"E Rodriguez","year":"2021","unstructured":"Rodriguez E, Boelaars K, Brown K, Eveline Li R, Kruijssen L, Bruijns SC, van Ee T, Schetters ST, Crommentuijn MH, van der Horst JC, van Grieken NC (2021) Sialic acids in pancreatic cancer cells drive tumor-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat Commun 12(1):1270","journal-title":"Nat Commun"},{"key":"4884_CR147","unstructured":"Sabat\u00e9 E, editor (2003) Adherence to long-term therapies: evidence for action. World Health Organization"},{"issue":"1","key":"4884_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2008.10.126","volume":"58","author":"MS Sabel","year":"2009","unstructured":"Sabel MS (2009) Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58(1):1\u20131","journal-title":"Cryobiology"},{"issue":"6876","key":"4884_CR149","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/bmj.306.6876.489","volume":"306","author":"MP Samuels","year":"1993","unstructured":"Samuels MP, Poets CF, Noyes JP, Hartmann H, Hewertson J, Southall DP (1993) Diagnosis and management after life threatening events in infants and young children who received cardiopulmonary resuscitation. BMJ 306(6876):489\u2013492","journal-title":"BMJ"},{"issue":"8","key":"4884_CR150","doi-asserted-by":"publisher","first-page":"e005147","DOI":"10.1136\/jitc-2022-005147","volume":"10","author":"RE Sanborn","year":"2022","unstructured":"Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE (2022) Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer 10(8):e005147","journal-title":"J Immunother Cancer"},{"issue":"15_suppl","key":"4884_CR151","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.4008","volume":"26","author":"DJ Sargent","year":"2008","unstructured":"Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A, Gallinger S (2008) Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26(15_suppl):4008","journal-title":"J Clin Oncol"},{"issue":"22","key":"4884_CR152","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.3748\/wjg.v20.i22.6809","volume":"20","author":"Z Saridaki","year":"2014","unstructured":"Saridaki Z, Souglakos J, Georgoulias V (2014) Prognostic and predictive significance of MSI in stages II\/III colon cancer. World J Gastroenterol: WJG 20(22):6809","journal-title":"World J Gastroenterol: WJG"},{"issue":"5","key":"4884_CR153","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato H, Okonogi N, Nakano T (2020) Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol 25(5):801\u2013809","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"4884_CR154","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S (2016) Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 13(4):228\u2013241","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4884_CR155","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","volume":"2","author":"M Saxena","year":"2018","unstructured":"Saxena M, Balan S, Roudko V, Bhardwaj N (2018) Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng 2(6):341\u2013346","journal-title":"Nat Biomed Eng"},{"issue":"7","key":"4884_CR156","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","volume":"30","author":"AB Schrock","year":"2019","unstructured":"Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D (2019) Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 30(7):1096\u20131103","journal-title":"Ann Oncol"},{"issue":"28","key":"4884_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8(28):86","journal-title":"Front Oncol"},{"issue":"3","key":"4884_CR158","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14712\/fb2024070030123","volume":"70","author":"J Se\u0148avov\u00e1","year":"2024","unstructured":"Se\u0148avov\u00e1 J, Rajmonov\u00e1 A, He\u0159man V, Jura F, Ve\u013easov\u00e1 A, Hamova I, Tkachenko A, Kupcov\u00e1 K, Havr\u00e1nek O (2024) Immune checkpoints and their inhibition in T-cell lymphomas. Folia Biol 70(3):123\u2013151","journal-title":"Folia Biol"},{"key":"4884_CR159","first-page":"362","volume":"10","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 10:362","journal-title":"BMJ"},{"issue":"8","key":"4884_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00041","volume":"13","author":"J Sia","year":"2020","unstructured":"Sia J, Szmyd R, Hau E, Gee HE (2020) Molecular mechanisms of radiation-induced cancer cell death: a primer. Front Cell Dev Biol 13(8):41","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"4884_CR161","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98(11):1753","journal-title":"Haematologica"},{"issue":"479","key":"4884_CR162","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat1500","volume":"11","author":"S Singhal","year":"2019","unstructured":"Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O\u2019Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ, Litzky L (2019) Human tumor-associated monocytes\/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med 11(479):eaat1500","journal-title":"Sci Transl Med"},{"issue":"6","key":"4884_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061440","volume":"13","author":"N Sobhani","year":"2021","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y (2021) CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers 13(6):1440","journal-title":"Cancers"},{"issue":"12","key":"4884_CR164","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. J Clin Oncol 40(12):1301\u20131311","journal-title":"J Clin Oncol"},{"issue":"9","key":"4884_CR165","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1164\/rccm.200202-070SO","volume":"166","author":"SG Spiro","year":"2002","unstructured":"Spiro SG, Porter JC (2002) Lung cancer\u2014where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166(9):1166\u20131196","journal-title":"Am J Respir Crit Care Med"},{"key":"4884_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105579","author":"N Stewart","year":"2024","unstructured":"Stewart N, Daly J, Drummond-Guy O, Krishnamoorthy V, Stark JC, Riley NM, Williams KC, Bertozzi CR, Wisnovsky S (2024) The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2023.105579","journal-title":"J Biol Chem"},{"issue":"14","key":"4884_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1349081","volume":"10","author":"J Su","year":"2024","unstructured":"Su J, Fu Y, Cui Z, Abidin Z, Yuan J, Zhang X, Li R, Zhao C (2024) Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Front Pharmacol 10(14):1349081","journal-title":"Front Pharmacol"},{"issue":"1","key":"4884_CR168","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/cas.15999","volume":"115","author":"T Sugi","year":"2024","unstructured":"Sugi T, Katoh Y, Ikeda T, Seta D, Iwata T, Nishio H, Sugawara M, Kato D, Katoh K, Kawana K, Yaguchi T (2024) Scd1 inhibition enhances the effector functions of CD8+ T cells via ACAT1-dependent reduction of esterified cholesterol. Cancer Sci 115(1):48\u201358","journal-title":"Cancer Sci"},{"issue":"1","key":"4884_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D (2023) Immune checkpoint therapy for solid tumors: clinical dilemmas and future trends. Signal Transduct Target Ther 8(1):320","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4884_CR170","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","volume":"66","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, Torres A, Watson R, Kurth KH (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(6):90\u2013107","journal-title":"Urology"},{"issue":"1","key":"4884_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T (2021) Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 6(1):72","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4884_CR172","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","volume":"11","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H (2022) Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells 11(3):320","journal-title":"Cells"},{"issue":"12","key":"4884_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122897","volume":"14","author":"E Tasci","year":"2022","unstructured":"Tasci E, Zhuge Y, Camphausen K, Krauze AV (2022) Bias and class imbalance in oncologic data\u2014towards inclusive and transferrable AI in large scale oncology data sets. Cancers 14(12):2897","journal-title":"Cancers"},{"key":"4884_CR174","unstructured":"Therrien NR (n.d.) Doxorubicin and anti-PD-1\/CTLA-4 combination therapy improves the adaptive immune response in murine soft tissue sarcoma models. Master\u2019s thesis, University of Colorado Denver, Anschutz Medical Campus"},{"issue":"9","key":"4884_CR175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050185","volume":"5","author":"MJ Thun","year":"2008","unstructured":"Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, Flanders WD, Jee SH, Katanoda K, Kolonel LN, Lee IM (2008) Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 5(9):e185","journal-title":"PLoS Med"},{"issue":"2","key":"4884_CR176","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa042283","volume":"353","author":"WD Toff","year":"2005","unstructured":"Toff WD, Camm AJ, Skehan JD (2005) Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med 353(2):145\u2013155","journal-title":"N Engl J Med"},{"issue":"1","key":"4884_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05065-6","volume":"12","author":"G Tomasello","year":"2022","unstructured":"Tomasello G, Ghidini M, Galassi B, Grossi F, Luciani A, Petrelli F (2022) Survival benefit with adjuvant chemotherapy in stage III microsatellite-high\/deficient mismatch repair colon cancer: a systematic review and meta-analysis. Sci Rep 12(1):1055","journal-title":"Sci Rep"},{"issue":"5","key":"4884_CR178","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052517","volume":"22","author":"L Tripodi","year":"2021","unstructured":"Tripodi L, Vitale M, Cerullo V, Pastore L (2021) Oncolytic adenoviruses for cancer therapy. Int J Mol Sci 22(5):2517","journal-title":"Int J Mol Sci"},{"key":"4884_CR179","doi-asserted-by":"crossref","unstructured":"Tujios S, Stravitz RT, Lee WM (2022) Management of acute liver failure: update 2022. In: Seminars in Liver Disease. Thieme Medical Publishers, Inc., Vol. 42(03), pp 362\u2013378","DOI":"10.1055\/s-0042-1755274"},{"issue":"1","key":"4884_CR180","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","volume":"22","author":"S Vafaei","year":"2022","unstructured":"Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M (2022) Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 22(1):2","journal-title":"Cancer Cell Int"},{"key":"4884_CR181","first-page":"33","volume-title":"Regulation of cancer immune checkpoints: molecular and regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie S, Wiernicki B, Xu J (2020) Molecular and cellular functions of CTLA-4. Regulation of cancer immune checkpoints: molecular and regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy, vol 18. pp 33\u201359"},{"issue":"4","key":"4884_CR182","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ijc.25113","volume":"127","author":"M Van Dongen","year":"2010","unstructured":"Van Dongen M, Savage ND, Jordanova ES, de Briaire- Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PC, Van Der Burg SH, Gelderblom H, Van Hall T (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 127(4):899\u2013909","journal-title":"Int J Cancer"},{"issue":"1","key":"4884_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumor immunogenicity. Nat Commun 8(1):15618","journal-title":"Nat Commun"},{"issue":"36","key":"4884_CR184","volume":"1","author":"S Verfaillie","year":"2023","unstructured":"Verfaillie S, Lambrecht M, Berkovic P, Dooms C, Nackaerts K, de Van Vel AS, Vansteenkiste J, Wauters E (2023) Treatment of unresectable stage III NSCLC: real world cohort study and literature review. Cancer Treat Res Commun 1(36):100727","journal-title":"Cancer Treat Res Commun"},{"issue":"22","key":"4884_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00008","volume":"10","author":"K Vermaelen","year":"2019","unstructured":"Vermaelen K (2019) Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol 10(22):8","journal-title":"Front Immunol"},{"key":"4884_CR186","doi-asserted-by":"crossref","unstructured":"Vlaming M, He Y, Bremer E (2023) Advances in therapeutic targeting of the tumor necrosis factor receptor superfamily members for cancer immunotherapy. In: Handbook of cancer and immunology. Cham, Springer International Publishing, pp 1\u201373","DOI":"10.1007\/978-3-030-80962-1_196-1"},{"issue":"11","key":"4884_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.718350","volume":"14","author":"S Vogt","year":"2021","unstructured":"Vogt S, Mattner J (2021) NKT cells contribute to the control of microbial infections. Front Cell Infect Microbiol 14(11):718350","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"4884_CR188","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, Wayne AS (2021) Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol 18(6):379\u2013393","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4884_CR189","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","volume":"5","author":"YJ Wang","year":"2018","unstructured":"Wang YJ, Fletcher R, Yu J, Zhang L (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Gene Dis 5(3):194\u2013203","journal-title":"Gene Dis"},{"issue":"11","key":"4884_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672677","volume":"29","author":"P Wang","year":"2021","unstructured":"Wang P, Chen Y, Wang C (2021) Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front Oncol 29(11):672677","journal-title":"Front Oncol"},{"issue":"138","key":"4884_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112582","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Zheng J, Tan Z, Zhang Y, Wang H (2024) A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC. Int Immunopharmacol 10(138):112582","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4884_CR192","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10238-024-01482-1","volume":"24","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yang R, Xie Y, Zhou XQ, Yang JF, Shi YY, Liu S (2024) Comprehensive review of drug-mediated ICD inhibition of breast cancer: mechanism, status, and prospects. Clin Exp Med 24(1):230","journal-title":"Clin Exp Med"},{"key":"4884_CR193","doi-asserted-by":"crossref","unstructured":"Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ (2015) Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. In: Seminars in Oncology. WB Saunders, Vol. 42(4), pp 601\u2013616","DOI":"10.1053\/j.seminoncol.2015.05.007"},{"issue":"3","key":"4884_CR194","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrclinonc.2011.2","volume":"8","author":"II Wistuba","year":"2011","unstructured":"Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS (2011) Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 8(3):135\u2013141","journal-title":"Nat Rev Clin Oncol"},{"key":"4884_CR195","doi-asserted-by":"crossref","unstructured":"Xu F, Song Y, Iyyer M, Choi E (2023) A critical evaluation of evaluations for long-form question answering. Proc ACL 2023:3225\u20133245. Available from https:\/\/aclanthology.org\/2023.acl-long.181.pdf. Accessed 6 Dec 2025","DOI":"10.18653\/v1\/2023.acl-long.181"},{"issue":"10","key":"4884_CR196","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","volume":"25","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto TN, Kishton RJ, Restifo NP (2019) Developing neoantigen-targeted T cell\u2013based treatments for solid tumors. Nat Med 25(10):1488\u20131499","journal-title":"Nat Med"},{"issue":"6","key":"4884_CR197","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011474","volume":"13","author":"W Yang","year":"2025","unstructured":"Yang W, Guo Z, Ju H, Lu Y, Fei Y, Yin Y, Ren G, Yan M, Han C, Hu J (2025) IL-4-STAT6-induced high Siglec-G\/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma. J Immunother Cancer 13(6):e011474","journal-title":"J Immunother Cancer"},{"issue":"41","key":"4884_CR198","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf6290","volume":"7","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wu M, Cao D, Yang C, Jin J, Wu L, Hong X, Li W, Lu L, Li J, Wang X (2021) ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv 7(41):eabf6290","journal-title":"Sci Adv"},{"issue":"1","key":"4884_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28","journal-title":"Mol Cancer"},{"issue":"3","key":"4884_CR200","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/med4.75","volume":"2","author":"H Yuan","year":"2024","unstructured":"Yuan H, Yu K, Xie F, Liu M, Sun S (2024) Automated machine learning with interpretation: a systematic review of methodologies and applications in healthcare. Med Adv 2(3):205\u2013237","journal-title":"Med Adv"},{"issue":"23","key":"4884_CR201","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1158\/1078-0432.CCR-11-1048","volume":"17","author":"A Zaanan","year":"2011","unstructured":"Zaanan A, Fl\u00e9jou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, De Gramont A (2011) Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 17(23):7470\u20137478","journal-title":"Clin Cancer Res"},{"key":"4884_CR202","doi-asserted-by":"crossref","unstructured":"Zaheer S, Sureka N (2024) Unlocking new frontiers: novel immune targets for next-gen cancer immunotherapy. Authorea Preprints","DOI":"10.22541\/au.173170806.66836515\/v1"},{"issue":"24","key":"4884_CR203","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZ, Thuny F, Zubiri L, Chen CL, Sullivan RJ, Alvi RM (2020) Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor\u2013associated myocarditis. Circulation 141(24):2031\u20132034","journal-title":"Circulation"},{"issue":"21","key":"4884_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609705","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lou Y, Wang J, Yu C, Shen W (2021) Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment. Front Immunol 11(21):609705","journal-title":"Front Immunol"},{"issue":"4","key":"4884_CR205","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/med4.37","volume":"1","author":"H Zhang","year":"2023","unstructured":"Zhang H, Chen J, Zhang Q, Yu L, Li X, Wu S (2023) Oncogenic viral antigens for engineered T cell immunotherapy: challenges and opportunities. Med Adv 1(4):306\u2013317","journal-title":"Med Adv"},{"issue":"1","key":"4884_CR206","first-page":"45","volume":"21","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yu S, Peng Q, Wang P, Fang L (2024) Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies. Cancer Biol Med 21(1):45\u201364","journal-title":"Cancer Biol Med"},{"issue":"20","key":"4884_CR207","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.3390\/cancers14204975","volume":"14","author":"BW Zhao","year":"2022","unstructured":"Zhao BW, Zhang FY, Wang Y, Chen GM, Nie M, Zhao ZK, Chen XJ, Jiang KM, Nie RC, Chen YB (2022) LAG3-PD1 or CTLA4-PD1 inhibition in advanced melanoma: indirect cross comparisons of the CheckMate-067 and RELATIVITY-047 trials. Cancers 14(20):4975","journal-title":"Cancers"},{"issue":"16","key":"4884_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515027","volume":"6","author":"H Zhao","year":"2025","unstructured":"Zhao H, Huang S, Wu J, Lu Y, Zou Y, Zeng H, Li C, Wang J, Zhang X, Duan S, Liang W (2025) Efficacy and safety of first-line PD-1\/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis. Front Immunol 6(16):1515027","journal-title":"Front Immunol"},{"issue":"13","key":"4884_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915094","volume":"15","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ni Y, Liang X, Lin Y, An B, He X, Zhao X (2022) Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol 15(13):915094","journal-title":"Front Immunol"},{"issue":"7","key":"4884_CR210","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","volume":"42","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, Zhang Z, Wang Q, Yao J, Wang H, Yang W (2024) Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial. Cancer Cell 42(7):1258\u20131267","journal-title":"Cancer Cell"},{"issue":"10","key":"4884_CR211","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, Gogas H (2023) Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers 15(10):2718","journal-title":"Cancers"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04884-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04884-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04884-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:04:34Z","timestamp":1782101074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04884-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":211,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4884"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04884-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}